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Abstract
Chlamydial infection in koalas is common across the east coast of Australia and causes significant morbidity,
infertility and mortality. An effective vaccine to prevent the adverse consequences of chlamydial infections in koalas
(particularly blindness and infertility in females) would provide an important management tool to prevent further
population decline of this species. An important step towards developing a vaccine in koalas is to understand the
host immune response to chlamydial infection. In this study, we used the Pepscan methodology to identify B cell
epitopes across the Major Outer Membrane Protein (MOMP) of four C. pecorum strains/genotypes that are
recognized, either following (a) natural live infection or (b) administration of a recombinant MOMP vaccine. Plasma
antibodies from the koalas naturally infected with a C. pecorum G genotype strain recognised the epitopes located in
the variable domain (VD) four of MOMP G and also VD4 of MOMP H. By comparison, plasma antibodies from an
animal infected with a C. pecorum F genotype strain recognised epitopes in VD1, 2 and 4 of MOMP F, but not from
other genotype MOMPs. When Chlamydia-free koalas were immunised with recombinant MOMP protein they
produced antibodies not only against epitopes in the VDs but also in conserved domains of MOMP. Naturally infected
koalas immunised with recombinant MOMP protein also produced antibodies against epitopes in the conserved
domains. This work paves the way for further refinement of a MOMP-based Chlamydia vaccine that will offer wide
cross-protection against the variety of chlamydial infections circulating in wild koala populations.
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Introduction
The koala is the only surviving member of the family
Phascolarctidae and is considered an icon of Australia’s unique
biodiversity. Despite this esteem, wild koala populations in
geographically diverse regions throughout the country continue
to decline. This decline has been attributed to several variables
such as (a) habitat loss, resulting in fragmentation of koala
colonies [1]; (b) disease [2]; (c) motor vehicle trauma [3]; and
(d) dog attacks [4]. A recent study showed that addressing
disease, amongst the many variables affecting koala survival
would have the greatest potential impact on stabilising
population decline [2]. Disease caused by infections of the
obligate intracellular bacterial pathogen, Chlamydia pecorum,
is a major threat to the ongoing survival of this species [5]. C.
pecorum infections in koalas have been associated with a
spectrum of diseases ranging from keratoconjunctivitis (ocular
disease) leading to blindness, rhinitis and pneumonia, as well
as urinary and genital tract disease, resulting in inflammation
and fibrosis of the bladder and the upper female genital tract
[6-10]. An effective vaccine to prevent the complications of
chlamydial infections in koalas would provide a valuable
management tool to stop the decline in wild populations by (a)
reducing the infectious load in infected animals, and (b)
preventing the further development of chlamydial pathology in
healthy animals and development of pathology in already
infected animals.
An ideal chlamydial vaccine should be able to induce both
cellular and humoral immune responses in the host [11]. The
Major Outer Membrane Protein (MOMP), which constitutes
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60% of the chlamydial outer membrane, has been the most
widely used antigen either in its native or recombinant form in
several vaccine studies [12-15]. Initial efforts to develop a
MOMP-based vaccine demonstrated a vaccine induced cell-
mediated immune response lasting for more than a year as
well as a humoral immune response (Chlamydia-neutralizing
antibody) lasting > 35 weeks [16]. Following this study, our
group further evaluated the safety and efficacy of a C. pecorum
MOMP-based multi-subunit vaccine in diseased as well as
healthy koalas [17]. Strong antibody (including neutralizing
antibodies) and lymphocyte proliferation responses were
recorded in all vaccinated healthy and clinically diseased
koalas. Vaccine induced antibodies specific for MOMP G, one
of the thirteen known C. pecorum ompA genotypes (A-H;
unpublished data) were observed not only in plasma but also in
ocular secretions.
In the most recent study, we evaluated the immunogenicity
of a vaccine consisting of either monovalent or polyvalent
MOMPs [18]. Animals immunized with individual MOMPs
developed strong antibody and lymphocyte proliferation
responses to both homologous as well as heterologous MOMP
proteins. Importantly, we also showed that vaccine-induced
antibodies effectively neutralized heterologous strains of koala
C. pecorum in an in vitro assay. Finally, we also demonstrated
that the immune responses in monovalent as well as polyvalent
MOMP vaccine groups were able to recognize whole
chlamydial elementary bodies, illustrating the feasibility of
developing an effective MOMP-based C. pecorum vaccine that
could protect against a range of strains. A promising aspect of
our most recent trials [17,18] was the cross-reactivity of MOMP
antibody responses from vaccinated healthy and diseased
koalas, giving hope for the generation of a MOMP-based
vaccine that will offer wide cross-protection against the variety
of genetically distinct C. pecorum strains circulating in wild
koala populations. In the present study, we further investigated
the MOMP B cell epitopes responsible for the cross reactivity of
the vaccine induced plasma antibodies in our previous vaccine
trials. We examined (a) the specific MOMP epitopes that were
recognized by koalas naturally infected with C. pecorum, (b)
epitopes recognized by healthy animals immunized with either
MOMP A, MOMP F, MOMP G or MOMP A plus F, and (c)
epitopes recognized by the diseased animals immunized with
MOMP G.
Materials and Methods
Koalas used in this study
Nine koalas were analysed as part of this study, consisting of
(a) five wild animals with a current or recent C. pecorum
infection and overt signs of disease at the time of sampling,
and (b) four captive healthy animals, with no evidence of
infection or disease (Table 1). Among the diseased animals,
three koalas were tested and found to be infected with C.
pecorum ompA genotype F and the remaining two koalas were
tested and found to be infected with C. pecorum ompA
genotype G [17]. One koala (Popeye) in the C. pecorum G
group and two koalas (Nixon/Felix Pitt) in the C. pecorum F
group were subcutaneously immunized with a vaccine
consisting of MOMP G and ISC (adjuvant), as previously
described [17]. Kathy received the placebo (adjuvant only).
Four healthy animals with no signs of infection or disease were
immunized with individual MOMP types (A, F and G) or
together (A and F), respectively [18].
The sampling and analysis of samples from wild koalas
received for treatment at Australian Zoo Wildlife Hospital was
performed under permission of the Queensland State
Government Department of Environment and Heritage
Protection (Scientific Purposes Permit WISP 06056009). All
animal work was approved by the Queensland University of
Technology Animal Ethics Committee (Approval #0700000845
& #0700000559).
Sampling of the animals
Animals were sampled prior to immunisation (all 9 animals)
and then 20 weeks post immunisation (8 out of 9 animals).
Plasma was separated from anti-coagulated bloods by
centrifugation at 233xg for 5 min at 4°C. Samples were then
stored at -80°C for further analysis.
Screening for C. pecorum infections
Ocular and urogenital tract swab samples from all animals,
prior to immunisation were screened for the presence of C.
pecorum infections by 16S rRNA species-specific quantitative
PCR [19] and for the presence of C. pecorum MOMP specific
antibodies by immunoblotting [17].
Design of Biotinylated peptide library for screening
MOMP antibodies from koala plasma
A library of overlapping 15 amino acid peptides were
designed by our group and constructed by Mimotopes
(Melbourne, Australia). The full-length koala C. pecorum
MOMP sequence for MOMP F (Figure 1) was used to design
Table 1. List of diseased as well as healthy koalas in this
study with their qPCR status, infecting strain and clinical
disease observed during the study.
Koala
Identifier
Chlamydia
PCR status
Naturally
infected with C.
pecorum
(strain)
Clinical disease
status Immunization
Mars Bar + C. pecorum G Cystitis Not Immunised
Popeye [19] + C. pecorum G Conjunctivitis MOMP G
Nixon [19] + C. pecorum F Conjunctivitis MOMP G
Felix Pitt
[19] + C. pecorum F Conjunctivitis MOMP G
Kathy [19] + C. pecorum F Cystitis Placebo only
Amity [20] - - - MOMP A
Nessie [20] - - - MOMP F
Jaffa [20] - - - MOMP G
Guppy [20] - - - MOMP A + MOMPF
References are listed in the brackets.
doi: 10.1371/journal.pone.0074808.t001
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the first 63 overlapping (9 amino acid offset) 15 mer peptides.
In addition to peptides representing the complete 370 amino
acids of C. pecorum MOMP F, the four variable domain regions
of C. pecorum MOMPs A, G and H, and three peptides
representing two major predicted B cell epitopes in conserved
domains were also covered by the remaining 25 overlapping
15mer peptides. Each peptide consisted of a biotin molecule
linked to a spacer (-SGSG-) to prevent steric hindrance,
followed by the 15mer sequence with an offset of 9 amino
acids.
Biotinylated Peptide Enzyme Linked ImmunoSorbent
Assay
The wells of 96 well streptavidin coated plates pre-blocked
with BSA (Thermo, Fisher Scientific, Melbourne, Australia)
were coated individually with each of the 88 biotinylated
peptides at a concentration of 2 µg/well in 1X Phosphate
Buffered Saline Tween-20 and incubated for 2 hrs at room
temperature (22°C). Post incubation, the wells were washed 3X
with PBS-T and the individual plasma samples (diluted to
1/1000) were added to the wells (100 µl/well), respectively. The
plates were incubated overnight at 4°C followed by washing 4X
with PBS-T. The plates were then incubated with sheep anti-
koala IgG (1:4000 in PBS-T) (100 µl/well) and incubated for 1
hr at room temperature. Finally, after four washes, HRP-
labelled rabbit anti-sheep IgG (1:1000 Southern Biotech/In vitro
Technologies, Cleveland, Australia) was added (100 µl/well) to
the wells and incubated for 1 hr at room temperature. After five
washes with 1X PBS, 100 µl/well of ABTS
[2, 2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid),
Southern Biotech, Alabama, USA] substrate solution was
added and incubated for 10 min at room temperature. The
optical density was then read at 405 nm (Bio-Rad, North Ryde,
Australia). Background for each sample was calculated from
the mean plus twice the standard deviation of the negative
wells (no sera added). In an attempt to minimise the inter-
assay variability and truly reflect the differences in antibody
response profiles between samples, (a) the assay was
performed on both pre- and post-immunised samples of each
animal alongside on the same day, and (b) the background
absorbance (green line) used for comparing the response
profiles from pre- and post-immunisations was a result of the
mean plus two times the standard deviation of the negative
controls of both samples.
Western blot
Western blots to assess the specificity of the koala plasma to
different C. pecorum MOMP proteins was performed as
previously described [17]. In brief, 5 µg aliquots of each of the
MOMP’s A, F, G and H was loaded onto 12% SDS-PAGE gels
and run at 110V for 1hr. Following blotting onto a nitrocellulose
membrane at 90V for 1hr, membranes were blocked in skim
milk solution for 1hr. Plasma samples from 4 weeks prior to
immunization and 20 weeks post immunization (1:1000) were
then analysed by incubating onto respective blots overnight at
4°C. Membranes were then washed and sheep anti koala IgG
was added at 1:1000 dilution and left for an hour. After
incubation, membranes were further washed with TBST and
incubated with HRP-labelled rabbit anti-sheep IgG (1:1000) for
1hr. Blots were then washed thoroughly with TBS and
visualised for bands by adding chemiluminescence substrate.
Results
Response profile of plasma from Chlamydia negative
koalas
Plasma from four healthy, pre-immunised, Chlamydia
negative koalas (Amity, Nessie, Jaffa and Guppy) were
evaluated against the 88 peptides in the MOMP peptide library.
Figure 2 shows each individual animal’s response (indicated by
the blue lines; A, B, C and D). There were weak absorbance
levels to all 88 peptides (except for peptide 22 in the conserved
domain) in all four healthy, Chlamydia-free animals. The
response profiles for each pre-immunisation sample was used
to establish a background response profile for analysis of post-
immunisation samples.
Vaccination elicits cross-reactive MOMP antibodies in
Chlamydia free animals immunized with recombinant
MOMP proteins A, F and G
Figure 2A shows the specificity of the antibodies produced
by a Chlamydia negative koala (Amity) following immunization
with recombinant MOMP A. Interestingly, when compared to
animals immunised with other MOMPs (Figure 2), Amity’s post
immunised sample had a better (but not extremely high)
response profile against the majority of the same peptides
recognized by her own pre-immunised sample. Immunization
also induced cross-reactive antibody against three other
MOMPs, as shown in the immunoblots of Figure 2A. Another
Chlamydia negative koala (Nessie) was immunized with
recombinant MOMP F protein and by 20 weeks post
Figure 1.  Layout of C. pecorum MOMP peptide library.  Peptides 1 to 63 represent five conserved domains (straight lines)
interspersed by four variable domains (boxes) of MOMP F. Peptides 64 to 88 represent four variable domains of MOMP A, MOMP
G and MOMP H, respectively.
doi: 10.1371/journal.pone.0074808.g001
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vaccination produced plasma antibodies (Figure 2B) that
reacted strongly against epitopes in (a) the conserved domains
(peptides 16 and 27), (b) variable domains of MOMP F
(peptides 13, 14 and 38) and; (c) variable domain two of
MOMP H (peptide 84) (Table 2). Immunisation of a Chlamydia
negative animal (Jaffa) with MOMP G protein resulted in
Figure 2.  B cell epitope mapping across four MOMPs in Chlamydia free koalas after vaccination.  Response profiles and
immunoblots of four Chlamydia free koalas vaccinated with MOMP A (A), MOMP F (B), MOMP G (C) and MOMP A as well as
MOMP F (D), respectively. The blue line indicates the absorbance of pre immunized samples collected from individual Chlamydia-
negative animals. The red line indicates the 20 weeks post immunized sample. The green line indicates the background (Mean and
two times standard deviation of negative controls).
doi: 10.1371/journal.pone.0074808.g002
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antibodies that primarily recognise various linear epitopes in
the conserved domains of MOMP (peptides 35, 44, 55 and 87)
(Figure 2C). Finally, when a Chlamydia negative animal was
immunised with a combination of two MOMP proteins (A plus
F) it produced antibodies that recognised the epitopes in
conserved domains (peptides 2 and 19) as well as the variable
domain one of MOMP F (peptides 13 and 14) (Figure 2D)
(Table 2). Both the animals immunised with MOMP F (one in
combination with MOMP A) gave the strongest reaction to
peptide 13 (DSVSLQERENPAYGK) and its overlapping
peptide 14 (ERENPAYGKHMHDAE). Additionally, to
corroborate the Pepscan data, we performed immuno-blot
assays on both pre- and post-immunised plasma at the same
time points, using similar concentrations of plasma (1:1000)
used in Pepscan assay for each animal. Although the pre-
immunised samples were negative against four MOMP
variants, the samples collected 20 weeks after immunisation
developed cross-reacting antibodies to various MOMPs (Figure
2)
Response profiles of plasma antibodies in koalas with
natural Chlamydia infections
Figure 3 shows the specificity of plasma antibodies produced
in two animals [Popeye (Figure 3A) and Mars Bar (Figure 3B)]
naturally infected with C. pecorum genotype G when compared
to the response of four Chlamydia negative animals. Both
animals had a similar response profile to the Chlamydia free
animals for 84 out of 88 peptides, however, plasma from these
two diseased animals reacted strongly with epitopes from
variable domain four of MOMP G (298’-
TLLGEATQVDNSNKF;peptide 79) and the equivalent epitope
in MOMP H (298’-TLLGQATQVDNSNKF;peptide 85),
respectively. Interestingly, when this epitope of 15 amino acid
length was aligned with all four MOMPs (Figure 3C), there are
nine amino acid differences between MOMP G and MOMP A,
eight amino acid differences between MOMP G and MOMP F
but only one amino acid difference between MOMP G and
MOMP H, which presumably explains the cross reactivity of
plasma antibodies to MOMP G and MOMP H. Apart from the
epitopes in the variable domains, plasma antibodies from Mars
Bar also recognised two unique B cell epitopes in the
conserved regions of MOMP (peptides 16 and 27), consistent
with differences in immune responses in out-bred animals.
Figure 4 shows the specificity of the plasma antibodies in two
animals [Nixon (Figure 4A), and Felix Pitt (Figure 4B)] naturally
infected with C. pecorum genotype F, again compared to the
response of the four Chlamydia negative animals. Although
both these wild koalas were infected with C. pecorum F, they
had different responses to the MOMP peptides. Nixon (Figure
4A) produced antibodies to the three epitopes in the variable
domains, SMGQAPSTNSPADSV (variable domain one;
peptide 11), GLIGISGSDLNSKVP (variable domain two;
peptide 23) and LNMTTWNPTLLGEAT (variable domain four;
peptide 49) whereas Felix Pitt (Figure 4B) produced antibodies
to epitopes GLIGISGSDLNSKVP (variable domain two; peptide
23) and EATSVNAGNKYADVL (variable domain four; peptide
51). For the epitope recognized by both animals in variable
domain two (Figure 4C), we found four amino acid differences
between MOMP F and the other three MOMPs. Interestingly,
within the MOMP variable domain four (Figure 4D), both
animals recognised two different epitopes VD4 (1) and VD4 (3),
respectively, although the epitopes shared three amino acids
between them. At VD4 (1) there are 3-5 amino acid differences
between the various MOMPs and 5-8 amino acid differences
between various MOMPs at VD4 (3). Another animal (Kathy),
naturally infected with C. pecorum F also produced antibodies
to epitopes DSVSLQERENPAYGK (variable domain one;
peptide 13) and NQTLPLPITAGTATD (variable domain three;
peptide 37) of MOMP F (Figure 5A).
Evaluation of MOMP antibody responses in a
Chlamydia infected animal administered with placebo
(adjuvant only)
A C. pecorum F infected koala when vaccinated with a
placebo (ISC) did not produce any antibodies to conserved
domains, but retained a similar reactivity pattern to the pre-
immunization sample (Figure 5A) by producing antibodies
predominantly to the variable domains one and three of MOMP
F.
Enhancement of a broader repertoire of MOMP
antibodies in naturally diseased animals following
immunization with recombinant MOMP protein
Figure 5B illustrates the vaccine induced production of
antibodies to various epitopes in a koala that was previously
naturally infected with C. pecorum G. Interestingly, after
immunization with recombinant MOMP G protein there was a
significant production of antibodies against previously
recognized epitopes (induced by natural infection) in variable
domain four of MOMP G and H and additionally to the
conserved domains (Table 2). Figure 5C shows the
enhancement of antibodies in a C. pecorum F infected koala
after immunization with MOMP G protein. The major epitopes
recognized fall in the conserved domains as well as the
variable domain four of MOMP F and variable domain one of
MOMP H (Table 2).
Discussion
Studies in various animal models (mice, guinea pigs and
non-human primates) of Chlamydia infection, have suggested a
significant requirement for antibody-mediated immune
responses (neutralising antibodies) along with cellular immune
responses (Th1) for an effective vaccine. Morrison et al. [20]
demonstrated a significant role for B cells and CD4+ T cells but
not CD8+ T cells, in resistance to C. trachomatis genital tract
reinfection. In a follow up study, Morrison et al. [21]
subsequently showed that antibody-mediated immune
responses were critical in the resolution of secondary genital
tract infection in mice but this resolution was independent of
both CD4+ and CD8+ T cells. Hence, optimising the antibody
response is essential for effective chlamydial vaccine
development.
Our previous koala Chlamydia vaccine trials [17,18] have
demonstrated strong vaccine induced humoral immune
responses in healthy koalas as well as vaccine enhanced
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immune responses in naturally infected koalas, at both
systemic and mucosal sites. One particularly encouraging
aspect of these studies was the observation of cross-reactive
antibodies in vaccinated healthy and diseased animals [17] that
recognized MOMP from different C. pecorum strains. The
functionality of these antibodies was demonstrated by their
ability to cross-neutralize heterologous C. pecorum infections,
in vitro [18].
In our current study, we used Pepscan methodology to
investigate linear epitopes along the entire MOMP protein to
determine the specificity of the antibody responses produced
following, (a) natural live infection, (b) recombinant MOMP
vaccination, (c) recombinant MOMP vaccination on top of
natural live infection. The 15mer peptides (overlapping by 9
amino acids) covered the full length of koala C. pecorum
MOMP F protein, as well as the variable domain regions for
koala C. pecorum MOMPs A, G and H. When we evaluated
immune sera from four naturally infected koalas, interestingly,
only six linear epitopes were recognised. Five of these epitopes
(peptides 23, 49, 51, 79 and 85) were located in the variable
domains, while the other epitope (peptide 53) was in a
conserved domain. These naturally recognised epitopes
presumably represent the surface-exposed regions on intact
chlamydial EBs/RBs that are recognised during a natural live
infection. Of these six naturally recognised MOMP epitopes,
none were recognised by all four koalas. One possible
explanation for this could be due to major histocompatibility
complex restriction in these out bred koalas [22]. We found that
different epitopes were recognised in koalas infected with
different C. pecorum genotypes (peptides 79 and 85 were
recognised by C. pecorum G infected koalas only; peptides 23,
Figure 3.  B cell epitope mapping across four MOMPs in naturally, C. pecorum genotype G infected koalas.  Response
profiles of two wild koalas naturally infected with C. pecorum G, Popeye (A) and Mars Bar (B) across MOMP peptide library and
amino acid alignment of four MOMPs at VD4 epitope (C) (dots represent the consensus). Representative blot of plasma from the
koalas infected with C. pecorum G against four recombinant full length MOMP proteins (D). The blue line indicates the mean of
absorbance of four Chlamydia free animals. The red line indicates the Chlamydia infected animal. The green line indicates the
background (Mean and two times standard deviation of negative controls).
doi: 10.1371/journal.pone.0074808.g003
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49 and 51 were recognised by C. pecorum F infected koalas
only).
The in silico B cell prediction algorithm has predicted major
epitopes in all four variable domains across C. pecorum
MOMPs [18], however koalas naturally infected with C.
pecorum G genotype produced antibodies only to the linear
epitopes of variable domain four of MOMP G and MOMP H.
This cross reactivity to MOMP G and MOMP H was similar to
the immunoblot data we observed (Figure 3D). Interestingly, an
alignment of the amino acids at this epitope, revealed only one
amino acid difference between them i.e. Glutamic acid (E) in
MOMP G and Glutamine (Q) in MOMP H (Figure 3C). Amino
acids at variable domain four between MOMP G and H were
more similar (93.3% consensus) when compared to the
variable domain three (73.3% consensus), variable domain two
(69.2% consensus) and variable domain one (62.5%
consensus) regions, which explains the cross-reactivity of
antibodies to MOMP G and H. Among the koalas infected
naturally with C. pecorum F, one animal (Nixon) produced
plasma antibodies to three epitopes at the variable domains of
MOMP F (VD1, VD2 and VD4) whereas the other animal (Felix
Pitt) produced antibodies to epitopes in two variable domains of
MOMP F (VD2 and VD4). Both the animals (Nixon and Felix
Pitt) shared a common epitope located in variable domain two.
Even though there was 73.3% similarity between MOMP F and
MOMP A at this linear epitope, and 66.6% between MOMP F
and MOMP G/H, both koalas specifically produced antibodies
only to MOMP F (Figure 4C). Surprisingly, although both
targeting variable domain four of MOMP F, antibodies from
each animal recognised two different overlapping epitopes
within this domain (Figure 4D).
Pre-immunised plasma samples from four Chlamydia
negative koalas, with the exception of Amity, did not recognise
any of the epitopes except for peptide 22 (Figure 2). When we
evaluated sera from four Chlamydia negative koalas that were
immunised either with individual recombinant MOMP proteins
Figure 4.  B cell epitope mapping across four MOMPs in naturally, C. pecorum genotype F infected koalas.  Response
profiles of two wild koalas naturally infected with C. pecorum F, Nixon (A) and Felix Pitt (B) across MOMP peptide library. Alignment
of four MOMPs at an epitope at variable domain two (C), and two overlapping epitopes at variable domain four (D) (dots represent
the consensus). The blue line indicates the mean of absorbance of four Chlamydia free animals. The red line indicates the
Chlamydia infected animal. The green line indicates the background (Mean and two times standard deviation of negative controls).
doi: 10.1371/journal.pone.0074808.g004
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(A, F and G) or a combination of two recombinant MOMP
proteins (A and F), we observed an epitope response that was
different to the response seen with naturally infected koalas
(Figure 2) (Table 2). In these four immunised koalas, a total of
15 epitopes were recognised and eight of these epitopes were
different to the epitopes recognised during a natural live
infection. Only five of these vaccine induced epitope antibodies
were in the variable domains of MOMP F and MOMP H, while
10 were in conserved domains. Furthermore, a koala
immunised with both recombinant MOMPs (A and F) did not
Figure 5.  B cell epitope mapping across four MOMPs in Chlamydia infected koalas after administration with placebo or
vaccine.  Response profile of a C. pecorum F infected koala administered with a placebo (adjuvant only) across our MOMP peptide
library (A). Response profiles of a naturally infected C. pecorum G koala immunized with recombinant MOMP G (B), and a naturally
infected C. pecorum F koala immunized with recombinant MOMP G (C) across our MOMP peptide library. The blue line represents
the absorbance of the pre-immunized sample. The red line represents the 20 weeks post-immunized sample. The green line
indicates the background (Mean and two times standard deviation of negative controls).
doi: 10.1371/journal.pone.0074808.g005
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show any extra boosting effect to the conserved domains in
particular, when compared to animals immunized with a single
MOMP. This data strongly correlates with the observation of no
significant difference in the cross-reactivity of antibodies post-
vaccination between the individual and dual MOMP groups, as
shown in Figure 2 and previously observed [18]. None of the in
silico predicted B cell epitopes in the conserved domain [18]
were recognized by the koalas; however antibodies to various
other epitopes in conserved domains were elicited.
Early studies by Girjes et al. [23] reported in vitro
neutralisation with sera from naturally infected koalas.
However, in their study, less than 50% of the sera showed in
vitro neutralisation activity and this varied between koalas. By
comparison, the four koalas that were given a recombinant
MOMP vaccine in our current study were all previously shown
by Kollipara et al. [17] to produce in vitro neutralising
antibodies. Although animals were immunized with single
recombinant C. pecorum MOMPs, they still effectively cross
neutralized the heterologous infections. Interestingly, there was
no significant difference between individual and combined
MOMP groups (MOMP A and MOMP F) in cross neutralization
of C. pecorum infections. This is very encouraging from a
vaccine development perspective, for the fact that seven of the
recognised epitopes were in conserved domains and therefore
conserved across all 13 C. pecorum MOMP genotypes (data
not shown) that we currently have sequence information for,
bodes well for wider cross neutralisation. It has also become
evident from studies in naturally infected koalas that strong,
long lasting protection from the neutralising antibodies does not
result in natural infections [18]. Hence, an effective vaccine will
need to improve on the existing natural immune response.
In the final aspect of our study, we evaluated the specificity
of the response of koalas naturally infected with C. pecorum
and then administered the recombinant MOMP vaccine. This is
critical because, if the vaccine has to be delivered to wild
populations, which already have 20-50% C. pecorum infections
levels (Kollipara et al., 2013; unpublished data), it has to be
effective in these groups. In the naturally infected vaccinated
animals, a total of eight vaccine induced epitopes were
recognised (Table 2). Out of eight epitopes, six were
recognised in conserved domains and the remaining two in the
variable domains (peptides 50 and 83).
In conclusion, although this study has dealt with the
specificity of the polyclonal antibodies against MOMP in wild
(outbred) koalas, known to have highly variable MHC Class II
genes [22]. We have primarily focussed on expanding the
findings (highly specific as well as cross-recognising humoral
immune responses) from our previous studies [17,18]. In this
study, we have shown, (a) specific MOMP B cell linear
epitopes recognised in C. pecorum G and F genotype infected
wild koalas and (b) MOMP linear epitopes responsible for the
production of cross recognition antibodies in post-vaccinated
healthy and diseased koalas. The findings from this study
provides further insights into (a) screening various potential B
cell epitopes using the Pepscan methodology in other
chlamydial antigens, such as chlamydial heat shock protein
(hsp60) [24] and thereby (b) developing diagnostic assays
which aid in screening various healthy as well as diseased
koalas. Using such findings as a proof of concept, a recent
study [25] has identified new peptide antigens from C.
trachomatis infected women and demonstrated the potential to
develop an epitope-based serological diagnostic assay. Since
both humoral and cell mediated responses are critical for a
protective immune response against persistent chlamydial
infections, our next step is to apply this screening assay to
identify several potential T cell epitopes in healthy and
diseased koalas.
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